Medicare drug price negotiation
Everything filed under system in our medical research coverage, the 39 reports filed on it so far.
ArriVent's furmonertinib fails key lung cancer trial endpoint
ArriVent BioPharma's oral lung cancer drug furmonertinib failed to significantly delay tumor progression versus chemotherapy in a late-stage study...
Amgen's Sjögren's drug succeeds in first Phase 3 trial
Amgen's experimental drug dazodalibep met its primary goal in a Phase 3 study for Sjögren's syndrome, showing early and sustained symptom improvement.
Novo Nordisk partners with Anthropic to accelerate drug discovery
Novo Nordisk has entered a collaboration with AI company Anthropic to speed up drug discovery and development.
FDA launches pilot to accelerate phase 1 trials
The FDA has opened a pilot program pairing drug sponsors with qualified research institutions to expedite IND reviews.
Cullinan and Taiho drug extends lung cancer progression-free survival
In a phase 3 trial, adding zipalertinib to chemotherapy improved median progression-free survival to 14.5 months, a six-month gain over chemo alone.
GSK's risvutatug rezetecan shows 18.5-month median overall survival
GSK and Hansoh Pharma's antibody-drug conjugate risvutatug rezetecan achieved a median overall survival of 18.5 months in a phase 3 trial for...
IL-33 Inhibitor Tozorakimab Cuts COPD Exacerbations
The biologic drug tozorakimab, which targets interleukin-33, significantly reduced the rate of moderate and severe exacerbations in patients with...
GLP-1 Drugs Linked to Fewer Asthma, COPD Attacks in Study
A large real-world study presented at the ERS Congress found patients with asthma or COPD who started a GLP-1 drug had a 14% lower risk of severe...
Roivant's lung hypertension drug hits Phase 2 goals
Roivant's mosliciguat reduced a key lung pressure measure by 56% in a Phase 2 trial for PH-ILD, with analysts citing multi-billion dollar potential.
Novartis Phase 3 Trial Fails for Lp(a) Drug Pelacarsen
Novartis's pelacarsen, an antisense drug developed with Ionis to lower lipoprotein(a), did not reduce major cardiovascular events in high-risk...
Novo Nordisk ends two more phase 3 trials
Novo Nordisk has discontinued two late-stage heart failure trials for its drug ziltivekimab after a data review.
Induced Proximity Therapies Gain Ground After First PROTAC Approval
The first FDA-approved PROTAC drug for breast cancer has validated a new class of medicines that work by bringing proteins together.
Novartis, Ionis heart drug fails in major Phase 3 trial
Novartis and Ionis Pharmaceuticals' experimental drug pelacarsen failed to reduce heart attacks, strokes or death in a Phase 3 study of over 8,000...
AbbVie's dual-acting myeloma drug etentamig meets Phase 3 endpoint
AbbVie reported that its bispecific antibody etentamig met the primary endpoint in a Phase 3 trial for multiple myeloma.
FDA Seeks Public Input on Botanical Drug Development
The FDA has launched a public request for information to identify challenges and opportunities in developing botanical prescription drugs.
AI startup Superluminal raises $60M for first drug candidate
AI drug discovery firm Superluminal Medicines has raised $60 million to advance its first candidate, an oral therapy targeting the MC4R receptor.
U.S. Overdose Deaths Drop 27% in 2024
A new Commonwealth Fund report details a sharp decline in U.S. drug overdose deaths in 2024, with preliminary 2025 data showing a continued drop.
Natera partners with Angiex on cancer trial
Natera has partnered with Angiex to evaluate its Signatera blood test in a phase 1 trial of the cancer drug AGX101.
Heart Failure Drug Combo Effects Modeled
A pooled analysis of 38,753 patients from nine trials provides individualized estimates for how combinations of modern heart failure drugs affect...
FDA approval ignites orexin drug race
Takeda's orexin-mimicking drug Orzeyful won FDA approval in August for narcolepsy type 1, with experts dubbing the class the 'GLPs of neuroscience'...
Genentech pays $45M for DualityBio ADC pact
Roche's Genentech will pay DualityBio $45 million upfront for rights to antibody-drug conjugates designed for patients who progress after existing...
AstraZeneca, Amgen's Tezspire succeeds in Phase 3 eosinophilic esophagitis trial
AstraZeneca and Amgen's Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, potentially expanding the label for the immunology drug.
AusperBio raises $120M for hepatitis B trial
AusperBio Therapeutics raised $120 million in a series C round led by RA Capital to advance its hepatitis B drug candidate AHB-137 into phase 3...
FDA clears three updated COVID-19 vaccines
The FDA approved updated COVID-19 vaccines from Pfizer, Moderna, and Novavax. Moderna also raised $2.6 billion for its cancer drug business.